What disease is Elzonris (tagraxofusp-erzs) used to treat?

Elzonris is used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) .

Elzonris (tagraxofusp-erzs) is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.

BPDCN is a rare and aggressive hematologic cancer characterized by the malignant proliferation of plasmacytoid dendritic cells (pDCs). It typically presents in the bone marrow, peripheral blood and/or skin, and may also involve the lymph nodes and viscera. It often presents as, or can be mistaken for, acute myeloid leukemia, non-Hodgkin’s lymphoma, acute lymphocytic leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia, as well as other malignancies with skin manifestations.

Diagnosis of BPDCN involves identifying cell surface markers, including the key marker CD123 which expressed in a number of hematologic malignancies, including BPDCN. BPDCN is more accurately diagnosed using an immunophenotypic triad of markers that includes CD123, CD4 and CD56.

Previous names for BPDCN include Blastic Natural Killer (NK) Cell Lymphoma and CD4+/CD56+ Hematodermic Neoplasm.

Elzonris is the first approved treatment for BPDCN and the first CD123-targeted therapy.